HC Wainwright Issues Positive Outlook for AUTL Earnings

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Autolus to ($0.30) from ($0.33) and reiterated a Buy rating with a $9.00 price target.
• Analyst views are mixed but the MarketBeat consensus is a Moderate Buy with a $8.50 target, comprising one Strong Buy, five Buys, one Hold and one Sell.
• Autolus reported Q1 EPS of ($0.34), missing estimates by $0.07 while revenue of $24.29M slightly beat expectations; the stock trades near $1.49 with a market cap of about $396.6M and roughly 72.8% institutional ownership.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Autolus Therapeutics in a research report issued on Thursday, April 9th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.30) for the quarter, up from their prior forecast of ($0.33). HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics' Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.21) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.36) EPS and FY2030 earnings at ($0.19) EPS.

A number of other research firms have also issued reports on AUTL. Truist Financial raised Autolus Therapeutics to a "strong-buy" rating in a report on Wednesday, March 25th. Needham & Company LLC reissued a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday. Zacks Research raised Autolus Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, March 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Finally, Mizuho decreased their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

Autolus Therapeutics Price Performance

AUTL opened at $1.49 on Monday. The firm has a market capitalization of $396.55 million, a P/E ratio of -1.38 and a beta of 2.04. The stock's 50 day moving average price is $1.48 and its two-hundred day moving average price is $1.53. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Friday, March 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.07). The business had revenue of $24.29 million during the quarter, compared to analyst estimates of $23.92 million. Autolus Therapeutics had a negative net margin of 381.40% and a negative return on equity of 99.05%.

Institutional Trading of Autolus Therapeutics

Several institutional investors have recently modified their holdings of AUTL. Invesco Ltd. grew its holdings in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Autolus Therapeutics by 809.4% during the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock worth $159,000 after buying an additional 91,222 shares during the period. Geode Capital Management LLC lifted its position in shares of Autolus Therapeutics by 90.5% during the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company's stock worth $375,000 after buying an additional 78,058 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company's stock worth $88,000 after buying an additional 11,289 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Autolus Therapeutics by 2,891.7% during the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company's stock worth $2,223,000 after buying an additional 942,540 shares during the period. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.